Assessing the Caprini Score for Risk Assessment of Venous Thromboembolism in Hospitalized Medical Patients - 26/04/16
, M. Todd Greene, PhD, MPH a, b, Vineet Chopra, MD, MSc a, b, c, Steven J. Bernstein, MD, MPH a, b, c, Timothy P. Hofer, MD, MSc a, c, Scott A. Flanders, MD a, bAbstract |
Background |
The optimal approach to assess risk of venous thromboembolism in hospitalized medical patients is unknown. We examined how well the Caprini risk assessment model predicts venous thromboembolism in hospitalized medical patients.
Methods |
Between January 2011 and March 2014, venous thromboembolism events and risk factors were collected from non-intensive care unit medical patients hospitalized in facilities across Michigan. After calculation of the Caprini score for each patient, mixed logistic spline regression was used to determine the predicted probabilities of 90-day venous thromboembolism by receipt of pharmacologic prophylaxis across the Caprini risk continuum.
Results |
A total of 670 (1.05%) of 63,548 eligible patients experienced a venous thromboembolism event within 90 days of hospital admission. The mean Caprini risk score was 4.94 (range, 0-28). Predictive modeling revealed a consistent linear increase in venous thromboembolism for Caprini scores between 1 and 10; estimates beyond a score of 10 were unstable. Receipt of pharmacologic prophylaxis resulted in a modest decrease in venous thromboembolism risk (odds ratio, 0.85; 95% confidence interval, 0.72-0.99; P = .04). However, the low overall incidence of venous thromboembolism led to large estimates of numbers needed to treat to prevent a single venous thromboembolism event. A Caprini cut-point demonstrating clear benefit of prophylaxis was not detected.
Conclusions |
Although a linear association between the Caprini risk assessment model and the risk of venous thromboembolism was noted, an extremely low incidence of venous thromboembolism events in non-intensive care unit medical patients was observed. The Caprini risk assessment model was unable to identify a subset of medical patients who benefit from pharmacologic prophylaxis.
Le texte complet de cet article est disponible en PDF.Keywords : Caprini risk assessment model, Deep venous thrombosis, Pharmacologic prophylaxis, Pulmonary embolism, Venous thromboembolism
Plan
| Funding: Blue Cross Blue Shield of Michigan and Blue Care Network supported data collection at each participating site and funded the data coordinating center but had no role in the study concept, interpretation of findings, or preparation, review, or final approval of the manuscript. |
|
| Conflict of Interest: PJG reports receiving royalties from Wiley Publishing and compensation for expert witness testimony. SJB reports receiving compensation as a consultant for Blue Care Network and the Michigan Department of Community Health, honoraria for various talks, and grants from Blue Cross Blue Shield of Michigan, Michigan Health and Hospital Association, Department of Veterans Affairs, National Institutes of Health, and the Agency for Healthcare Research and Quality. TPH reports receiving grant funding as an investigator or co-investigator from the Department of Veterans Affairs, National Institutes of Health, and Agency for Healthcare Research and Quality. SAF reports receiving compensation for consultancies for the Institute for Healthcare Improvement and the Society of Hospital Medicine; royalties from Wiley Publishing; honoraria for various talks at hospitals as a visiting professor; grants from the Centers for Disease Control and Prevention Foundation, Blue Cross Blue Shield of Michigan, Michigan Health and Hospital Association, and Agency for Healthcare Research and Quality; and compensation for expert witness testimony. |
|
| Authorship: All authors had access to the data and played a role in writing this manuscript. |
|
| PJG and MTG contributed equally as lead authors. |
Vol 129 - N° 5
P. 528-535 - mai 2016 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?
